Tirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a 39-amino acid synthetic peptide approved by the FDA under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It represents the first-in-class dual incretin agonist, distinguished from single-target GLP-1 agonists such as semaglutide by its additional GIP receptor activity.
A dual GIP and GLP-1 receptor agonist (39-amino-acid synthetic peptide), studied in metabolic research.
Primary research focus
- Glycemic-control research (SURPASS trial program)
- Weight-management research (SURMOUNT trial program)
- Cardiovascular research and insulin-sensitivity studies
Mechanism of Action
Published research indicates tirzepatide activates both the GIP and GLP-1 receptors, producing complementary metabolic effects. GLP-1 receptor agonism slows gastric emptying, enhances glucose-dependent insulin secretion, and suppresses glucagon release. GIP receptor agonism appears to enhance the insulinotropic response and may contribute to lipid metabolism and adipose tissue signaling. The dual mechanism research suggests improved glycemic control and greater weight reduction compared to selective GLP-1 receptor agonists alone (Frias JP, et al., 2021). The extended half-life (~5 days) is achieved through a C20 fatty diacid moiety enabling albumin binding, allowing once-weekly administration.
Research Applications
- Glycemic control research — SURPASS trial program demonstrated HbA1c reductions in type 2 diabetes (Rosenstock J, et al., 2021)
- Weight management research — SURMOUNT-1 showed mean body weight reductions of up to 22.5% at highest dose (Jastreboff AM, et al., 2022)
- Cardiovascular research — SURPASS-CVOT evaluating major adverse cardiovascular events; early data suggests benefit on cardiovascular markers
- Insulin sensitivity research — Published data indicates improvements in hepatic and peripheral insulin sensitivity
- Appetite regulation research — Central and peripheral appetite signaling modulation documented in clinical trials
Dosing Reference (Published Literature)
Published clinical trial protocols used escalating dosing schedules: 2.5 mg weekly for 4 weeks, escalating to 5 mg, 10 mg, or 15 mg weekly (subcutaneous injection). The escalation approach is designed to improve gastrointestinal tolerability. All published dosing data comes from manufacturer-sponsored Phase 2 and Phase 3 clinical trials.
Storage and handling: Tirzepatide is supplied as a clear, colorless to slightly yellow solution in pre-filled injection devices for clinical use and should be stored refrigerated at 2-8°C per the manufacturer's instructions.
Important: Tirzepatide is an FDA-approved prescription medication (Mounjaro, Zepbound) and should only be used under the supervision of a licensed healthcare provider. The information on this page is provided for educational and research purposes only and is not medical advice.
Synergistic Compounds
- Semaglutide — Same therapeutic axis (incretin-based weight management). Published research compares the two directly in the SURPASS-2 trial, where tirzepatide demonstrated superior HbA1c reduction (Frias JP, et al., 2021).
- AOD-9604 — Complementary lipolysis research. AOD-9604 targets the lipolytic fragment of growth hormone, potentially complementing incretin-mediated appetite suppression.
- Tesamorelin — Research suggests complementary effects on visceral adiposity reduction through distinct pathways (GHRH vs. incretin signaling).
- Retatrutide — Next-generation triple agonist (GIP/GLP-1/glucagon) currently in clinical development; research suggests potential for even greater metabolic effects.
Research Protocols Using This Compound
Key References
- Frias JP, et al. (2021) — SURPASS-2: Tirzepatide vs. semaglutide in type 2 diabetes (NEJM)
- Rosenstock J, et al. (2021) — SURPASS-1: Tirzepatide monotherapy (NEJM)
- Jastreboff AM, et al. (2022) — SURMOUNT-1: Tirzepatide for obesity (NEJM)
- Ludvik B, et al. (2021) — SURPASS-3: Tirzepatide vs. insulin degludec
- Min T & Bain SC (2021) — Dual incretin agonism review (Lancet)
:warning: Research Use Only (RUO). For educational and research reference purposes only. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease or condition. Always consult a qualified healthcare professional before making health-related decisions.
Frequently Asked Questions
Is Tirzepatide FDA-approved?
Yes. Tirzepatide is an FDA-approved prescription medication, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It should only be used under the supervision of a licensed healthcare provider.
What does the research literature show about Tirzepatide?
The published research record for Tirzepatide is summarized in the body of this article and the citations section. Pre-clinical and animal-model studies make up the bulk of the literature; human trial data is limited and is noted explicitly where it exists.
What are the documented synergistic compounds for Tirzepatide research?
See the Related Research sidebar for compounds that appear alongside Tirzepatide in the published literature. Detailed synergy notes will populate during the next vault expansion pass.
Where can I source Tirzepatide for research purposes?
See the Where to Source section above for vendors that supply Tirzepatide. Listed vendors are affiliate partners of Peptide Manager Pro; we earn a small commission on referred orders at no additional cost to the buyer.